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With the notable exceptions of the well-documented roles of 
 caspase-1 (Li et al., 1995; Ghayur et al., 1997) and -11 (Wang 
et al., 1998) in the processing and release of interleukin-1β 
(IL-1β) and interleukin-18 (IL-18), members of the caspase 
family have mainly been associated with the initiation and exe-
cution of apoptosis (Lamkanfi  et al., 2003). However, several 
recent reports have further substantiated the nonapoptotic roles 
of these so-called apoptotic caspases.
Caspases are synthesized as zymogens with a prodomain 
of variable length followed by a large and a small subunit (for 
review see Lamkanfi  et al., 2003). The large prodomains con-
tain a class of related protein recruitment motifs, such as the 
 caspase recruitment domain (CARD, caspases-1, -2, -4, -5, -9, 
-11, and -12) and the death effector domain (caspase-8 and -10). 
These prodomains allow recruitment in large protein complexes, 
eventually leading to caspase auto-activation and initiation of 
the apoptotic and infl ammatory pathways (Fig. 1). That is why 
large prodomain-containing caspases are often referred to as 
initiator caspases. These complexes consist of a platform pro-
tein that senses a trigger and that can either directly or by means 
of adaptors recruit specifi c large prodomain caspases. The 
death-inducing signaling complex (DISC) containing caspase-8 
is formed at the intracellular domain of death receptors, such as 
Fas, TRAIL receptor, and TNF receptor 1 (Peter and Krammer, 
2003; Varfolomeev et al., 2005). Fas-associated death domain-
containing protein (FADD) plays a crucial role in the re-
cruitment and activation of caspase-8 and -10 in the DISC. 
Mitochondrial damage results in release of cytochrome c, trig-
gering the assembly of the apoptosome complex that directly 
recruits caspase-9 (Cain et al., 2002). In vitro, caspase-2 is part 
of a high molecular weight complex containing the p53-induced 
death domain protein (PIDD) (Tinel and Tschopp, 2004). 
 Because the p53 tumor suppressor can elicit apoptosis in re-
sponse to DNA damage, it was suggested that this PIDDosome 
complex is formed under DNA-damaging conditions and func-
tions as a platform for caspase-2 activation. Last but not least, 
the infl ammatory caspases-1 and -5 have also been shown 
to be recruited to a number of protein platforms, named in-
fl ammasomes (Martinon and Tschopp, 2004). Typically, the 
platform of these complexes consists of members of the 
NACHT-LRRs (NLRs) (Martinon and Tschopp, 2005). NLRs 
are intracellular pathogen-recognition receptors that initiate 
infl ammatory signaling and/or cell death. These intracellular 
receptors are activated by different pathogen-associated mo-
lecular patterns or PAMPS such as bacterial RNA, lipopoly-
saccharide (LPS), or peptidoglycans.
Generally, recruitment of large prodomain caspases in 
these complexes induces a conformational change that is suf-
fi cient to activate these caspases, leading to autoproteolysis 
(Boatright and Salvesen, 2003). The short prodomain caspases 
are activated by proteolytic maturation by initiator caspases or 
other proteases, and are referred to as executioner caspases 
(caspases-3, -6, -7, and -14). The fi nal outcome of these proteo-
lytic cascades is the specifi c cleavage of a wide variety of sub-
strates that are implicated in apoptosis and infl ammation. Here, 
we discuss recent data that implicate caspases in nuclear factor 
κB (NF-κB) activation pathways. These nonapoptotic caspase 
functions involve both prodomain-mediated NF-κB activation, 
depending on recruitment of factors that initiate NF-κB activa-
tion, and a mechanism involving limited proteolytic activity of 
caspases. The latter mechanism relates to complex-mediated 
caspase activation that considers only a small fraction of the total 
cellular pool of a particular caspase. Under such conditions the 
initiator caspases remain associated with the initiating complex.
 NF-κB is a dimeric transcription factor involved in 
 immune regulation, apoptosis, cell proliferation, differentiation, 
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and carcinogenesis (Luo et al., 2005). NF-κB is sequestered in 
the cytoplasm as an inactive complex bound by a family of 
 inhibitors known as inhibitor of κB (IκB) proteins. In response 
to a variety of signaling events, the IκB kinase (IKK) complex 
phosphorylates IκB proteins. This post-translational modifi ca-
tion targets IκB for poly-ubiquitination and subsequent degra-
dation by the 26 S proteasome. The degradation of IκB proteins 
liberates the NF-κB transcription factor, allowing its transloca-
tion to the nucleus and activation of its target genes. Many sig-
naling pathways have been elucidated in NF-κB activation, such 
as those emanating from the TNF receptor family or the IL-1/
Toll-like receptor (TLR) family (Bonizzi and Karin, 2004). TLRs 
are a class of transmembrane cellular pathogen-recognition 
 receptors that survey the extracellular environment and trigger 
the innate immune response upon interaction with pathogen-
 associated products.
Prodomain-mediated NF-𝛋B activation 
by initiator caspases
The activation of NF-κB can be mediated, at least partially, by 
interaction motifs present in the prodomains of specifi c cas-
pases (Chaudhary et al., 2000; Kreuz et al., 2004; Lamkanfi 
et al., 2005). Indeed, several studies have shown that caspases-1, 
-2, -8, and -10 use similar mechanisms to activate NF-κB, but 
caspase-9, -11, and -12 do not activate this transcription factor 
(Chaudhary et al., 2000; Lamkanfi  et al., 2004, 2005).
The prodomains of caspases-2, -8, and -10 were shown to 
be capable of recruiting the NF-κB signaling molecules such as 
the E3 ubiquitin ligase activity containing factor, tumor ne-
crosis factor-receptor associated factor 2 (TRAF2), the kinase 
 receptor interacting protein 1 (RIP1), and NEMO/IKKγ, 
 eventually leading to increased kinase activity of the IKK 
 complex and NF-κB activation (Chaudhary et al., 2000; Shikama 
et al., 2003; Lamkanfi  et al., 2005) (Fig. 2). Caspase-2 complex 
formation, initiated by PIDD, has been associated with DNA 
damage repair (Tinel and Tschopp, 2004). The death domain–
containing serine/threonine kinase RIP1 is also recruited in the 
caspase-2 complex (Lamkanfi  et al., 2005), and has been shown 
to be essential for DNA damage–induced NF-κB activation 
(Hur et al., 2003). Therefore, the caspase-2 complex, also called 
PIDDosome (Tinel and Tschopp, 2004), may act as an integ-
rator or molecular switch between infl ammatory/anti-apoptotic 
and apoptotic signaling pathways (Zhivotovsky and Orrenius, 
2005). When DNA damage occurs, the PIDDosome complex 
may emit signals that activate NF-κB, hence allowing the cell 
to initiate cell survival and DNA repair pathways. Whether 
 caspase-2 has a physiological role in this pathway remains to be 
established. However, massive DNA damage may also generate 
too much proteolytically active caspase-2, leading to the con-
tinuous activation of apoptotic pathways. Similarly, caspase-8 
forms a complex with FLASH (FLICE-associated huge protein) 
and TRAF2 to initiate the NF-κB activation pathway during 
TNF signaling in fibroblast and epithelial cell lines (Jun 
et al., 2005). Although in these cells caspase-8 enzymatic 
 activity is apparently not required for TNF-induced NF-κB 
 acti vation, antisense-mediated caspase-8 depletion resulted in 
inhibition of TNF-induced NF-κB activation (Jun et al., 2005), 
Figure 1. Overview of the main protein complexes leading to the acti-
vation of large prodomain caspases. Complex formation is initiated by dif-
ferent ligands and sustained by several interaction motifs harbored in 
complex-residing proteins. The ligand-sensing motifs (e.g., leucine-rich re-
peats, WD40 repeats, and CRRs) initiate the formation of oligomers. Death 
domain and death effector domain or CARD–CARD homotypic interactions 
are crucial for the recruitment and activation of either caspase-8 in the DISC 
or caspase-9 in the apoptosome, respectively. Caspase-1 or -5 is activated 
in the different inﬂ ammasomes using different adaptors such as ASC/
PYCARD or CARDINAL, depending on the type of inﬂ ammasome. Several 
compounds that lead to inﬂ ammasome activation, called PAMPs (pathogen-
associated molecular patterns), such as bacterial RNA, LPS, or peptidogly-
cans, were identiﬁ ed. Caspase-2 is activated in the PIDDosome, using the 
adaptor molecule RAIDD upon DNA damage. How the nuclear damage 
triggers PIDDosome formation is currently not clear (see also text).
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suggesting that caspase-8 can have signaling activities indepen-
dent of its enzymatic activity.
In addition, Varfolomeev et al. (2005) showed that RNAi-
mediated knock-down of caspase-8 abrogates NF-κB activation 
induced by Apo2L/TRAIL (a member of the TNF family), 
which would occur when caspase-8, FADD, TRAF-2, RIP-1, 
and NEMO are recruited to a secondary cytosolic protein complex. 
The authors propose that caspase-8 enzymatic activity is impli-
cated in Apo2L/TRAIL-dependent NF-κB activation because 
addition of the pan-caspase inhibitor zVAD-fmk blocks this 
NF-κB activation. As NF-κB activation upon TRAIL receptor 
stimulation is observed rather late (hours), as compared with 
TNF-induced NF-κB activation (minutes), one cannot exclude 
that the identifi ed signaling complex is formed in response 
to general apoptotic stress, independently from the TRAIL 
receptor–bound DISC complex.
In contrast to caspases-2, -8, and -10, the caspase-1 
CARD domain is able to recruit the RIP2 kinase, which is in-
volved in TLR- and TcR-mediated NF-κB activation  (Kobayashi 
et al., 2002) (Fig. 2). Experiments using a RIP2 dominant-
 negative mutant have indicated that RIP2 mediates caspase-1 
CARD- induced NF-κB activation (Lamkanfi  et al., 2004). 
Caspase-1 can be recruited to different types of infl ammasomes 
that are initiated upon recognition of intracellular bacteria by 
NLRs ( Martinon and Tschopp, 2004). However, the in vivo rel-
evance of the activation of NF-κB by caspase prodomains re-
mains to be proven.
NF-𝛋B activation initiated by limited 
activation of initiator caspases
The initial observation that caspase inhibitors effi ciently abro-
gate the proliferation of primary human T cells in vitro and 
block the production of IL-2 in CD3/CD28-stimulated Jurkat 
cells suggested a role for caspases beyond the apoptotic context 
(Kennedy et al., 1999). Several reports have now provided ge-
netic evidence for the role of caspase-8 in the proliferation of 
immune cells (Chun et al., 2002; Salmena et al., 2003; Beisner 
et al., 2005; Su et al., 2005). Patients with inactivating muta-
tions in caspase-8 suffer from impaired proliferation of T, B, 
and NK cells (Chun et al., 2002).
Interestingly, mice in which caspase-8 was conditionally 
deleted in T cells suffered from similar defects (Salmena et al., 
2003). Peripheral T cells from these mice were unable to prolif-
erate after T cell receptor activation. IL-2 production after 
Figure 2. Proposed model for caspase-mediated NF-𝛋B activation. Multiple NF-κB signaling pathways can start from protein complexes containing the 
 initiator caspases-1, -2, -8, or -10. These pathways can depend on limited caspase activation resulting in minor enzymatic activity, as in the case of TcR, 
B-cell receptor, or TLR stimulation, or can start from prodomain-mediated recruitment of NF-κB signaling molecules as in TNF signaling. In addition, cleavage 
of PARP-1 by caspase-3 or -7 contributes to the transactivation of the NF-κB complex. “Limited caspase activation” is complex-mediated caspase activation 
that considers only a small fraction of the total pool of a particular caspase and that remains associated with the complex (active caspase depicted by 
a zigzag line and orange color).
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CD3/CD28 stimulation decreased signifi cantly in caspase-8–
defi cient T cells of both human and murine origin (Chun et al., 
2002; Salmena et al., 2003). Recently, the circle was closed by 
demonstrating the essential role of caspase-8 in T cell receptor 
(TcR)–induced NF-κB activation (Su et al., 2005), confi rming 
its function upstream of IL-2 production and human T cell 
 proliferation. Moreover, through reconstitution experiments 
in caspase-8–defi cient primary human T cells, enzymatically 
 active caspase-8, although unprocessed, was shown to be re-
quired for TcR-mediated NF-κB activation (Su et al., 2005). 
Through labeling of the active center it was estimated that only 
10–15% of the total caspase-8 content became enzymatically 
active after TcR stimulation. In contrast, TNF-induced NF-κB 
activation in T cells does not require caspase-8 enzymatic activ-
ity (Su et al., 2005), similar to observations in fi broblasts and 
epithelial cells, as discussed above (Jun et al., 2005). However, 
Salmena et al. (2003) did not observe a difference in TcR-
 stimulated NF-κB activation in caspase-8–defi cient mouse 
T cells. But these authors looked at NF-κB activation at a rather 
late time point (6 h), which may explain this apparent contradic-
tion concerning the involvement of caspase-8. In this respect, it 
has been shown previously that TRAF2 defi ciency only delays 
the kinetics of NF-κB activation in response to TNF, which nor-
mally occurs within minutes after treatment (Yeh et al., 1997). 
At a later time point (90 min), the extent of activated NF-κB in 
TRAF2-defi cient cells was equivalent to that in control cells.
Finally, T, B, and NK cells of patients with caspase-8 
 defi ciency do not show NF-κB activation after stimulation of 
antigen receptors, Fc receptors, or TLR-4 (Su et al., 2005), con-
fi rming the essential role of caspase-8 in NF-κB signaling. What 
is the mechanism of caspase-8 activation? It was shown that 
TcR stimulation triggered the recruitment of FADD and cas-
pase-8 to the CARMA-Bcl10-MALT1 (CBM) complex (Fig. 2). 
Absence of caspase-8 abrogated IKK recruitment and activation 
by the CBM complex. Although it is clear that enzymatically 
active caspase-8 is required, the identity of the substrates 
that need to be processed to initiate the NF-κB signaling cas-
cade remains to be determined. MALT1, also called paracas-
pase, harbors a caspase-like domain and a death domain, and is 
required for TcR-induced NF-κB activation (Ruland et al., 
2003). In addition to the CBM complex (van Oers and Chen, 
2005), TRAF2, TRAF6, and RIP2 were also shown to be essen-
tial for TcR-induced NF-κB activation (Kobayashi et al., 2002; 
Sun et al., 2004). Next to caspase-8, TLR-4 signaling shares 
several other molecules required for NF-κB activation with the 
TcR pathway, such as Bcl10 (Xue et al., 2003), RIP1 (Cusson-
Hermance et al., 2005), RIP2 (Kobayashi et al., 2002), and 
TRAF6 (Lomaga et al., 1999).
In contrast to B cells of patients harboring homozygous 
caspase-8 mutations (Su et al., 2005), the deletion of caspase-8 in 
murine B cells does not lead to impaired NF-κB activation upon 
TLR-4 stimulation (Beisner et al., 2005). Nevertheless, caspase-8–
defi cient B cells fail to proliferate in response to dsRNA or LPS, 
ligands for TLR-3 and TLR-4, respectively. It remains to be de-
termined whether the observed discrepancy in the response of 
human and murine caspase-8–defi cient B cells is due to a funda-
mental difference in the signaling pathways involved, to the 
 different nature of caspase-8 defi ciency, or to the different exper-
imental designs used to analyze NF-κB activation.
Why would activation of the apoptotic initiator caspase-8 
in one cellular context lead to initiation of apoptosis, whereas 
in another cellular context it activates NF-κB and induces 
 pro liferation? This may, at least in part, depend on the level of 
 caspase-8 activation. In proliferating cells, caspase-8 apparently 
remains unprocessed and would therefore be less active or at 
least only be active in the complex (Su et al., 2005). In FasL-
 induced apoptosis, caspase-8 is processed and strongly activated 
(Peter and Krammer, 2003). One way to modulate the level of 
caspase-8 activation is by the expression of c-FLIPL, a structural 
homologue of caspase-8 lacking caspase activity (Tschopp et al., 
1998; Micheau et al., 2002). High concentrations of c-FLIPL 
prevent full processing and release of active caspase-8 from the 
DISC, thus blocking the induction of cell death. Mice condi-
tionally lacking c-FLIP in T lymphocytes display severe defects 
in the development and proliferation of mature T cells (Chau 
et al., 2005; Zhang and He, 2005), possibly due to enhanced 
apoptosis sensitivity. However, TcR-induced activation of NF-κB, 
a caspase-8–dependent phenomenon as discussed above, in 
cFLIP-defi cient thymocytes appears largely intact (Zhang and 
He, 2005), whereas overexpression of cFLIP in Jurkat T cells 
increases NF-κB activation upon TcR ligation (Kataoka et al., 
2000). Therefore, the role of FLIP proteins in NF-κB activation 
remains unclear.
Indeed, confl icting data were reported in the literature 
concerning the role of caspase-8 and cFLIP in TcR-dependent 
NF-κB activation (Table I). The different levels of cFLIP ex-
pression in the different transgenic lines and the various extents 
of TcR triggering used may explain the apparent discrepancies 
observed in the literature. Indeed, it was shown that dependent 
on the anti-CD3 concentration used one can observe increased 
or reduced T cell proliferation in FLIP transgenic mice (Lens 
et al., 2002). Taking together the data presented in Table I, we 
can formulate the following conclusions. Defi ciency of either 
FADD, caspase-8, or cFLIP results in a common phenotype, 
namely reduced proliferative response upon TcR stimulation, 
demonstrating that these proteins act in a common pathway 
starting from the TcR. Although it has been extensively docu-
mented that NF-κB is required for T cell proliferation and acti-
vation (Li and Verma, 2002), the data discussed above suggest 
that TcR-induced proliferation does not solely depend on 
NF-κB activation. Viral FLIPs are proteins that resemble the pro-
domain of caspase-8 and inhibit the recruitment of caspase-8 
to the DISC (Ekert et al., 1999). Human herpesvirus 8 (HHV-8) 
vFLIP can also activate the NF-κB pathway, a property not 
shared by other vFLIPs (Chaudhary et al., 1999). This observa-
tion reminds us of the similar situation at the level of CARD-
containing caspases—some are capable of inducing NF-κB 
activation, whereas others are not (Lamkanfi  et al., 2004, 2005). 
Transgenic overexpression of HHV-8 vFLIP in the lymphoid 
compartment leads to constitutive NF-κB activation and in-
creased incidence of lymphomas, but has no signifi cant effect 
on Fas-induced apoptosis or the development and maturation of 
lymphocytes. Therefore, one can fairly conclude that FADD, 
caspase-8, and cFLIP are molecularly linked, at least in normal 
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T cell development and functioning. The exact role of these 
molecules in the NF-κB activation pathway remains to be deter-
mined. In this respect, it would be interesting to analyze the 
NF-κB signaling pathways in transgenic mice overexpressing 
the caspase-8 inhibitor CrmA (cytokine response modifi er A) 
(Smith et al., 1996). What really determines the fi nal decision 
between FADD/caspase-8–mediated apoptosis or FADD/
caspase-8–mediated proliferation is not clear today, but avail-
ability and specifi c proteolytsis of particular substrates will 
 certainly contribute.
NF-𝛋B activation initiated by limited 
activation of executioner caspases
Recently, a possible involvement of executioner caspases 
in NF-κB activation was suggested. Although cleavage of 
poly(ADP-ribose)polymerase-1 (PARP-1) at the DEVD site has 
been used as a canonical hallmark of caspase-3/-7 activation 
and apoptosis, the in vivo signifi cance of this cleavage was 
largely unknown. Initially, it was thought that PARP-1 cleavage 
in apoptotic cells represented a way to inactivate the DNA 
repair capacity. Recent genetic evidence suggests a novel role 
for caspase-generated fragments of PARP-1 in infl ammatory 
 responses. Indeed, LPS-stimulated macrophages from knock-in 
mice expressing caspase-resistant PARP-1 display impaired 
NF-κΒ–mediated gene activation despite normal binding of 
NF-κB to DNA (Petrilli et al., 2004).
As discussed above, caspase-8 is required for nuclear 
translocation of NF-κB (Su et al., 2005), whereas executioner 
caspases apparently act at the NF-κB transactivation level fol-
lowing DNA binding through a PARP-1–mediated mechanism 
(Petrilli et al., 2004) (Fig. 2). Indeed, it had previously been 
shown that PARP-1 can interact with both subunits of NF-κB 
(p50 and p65) and with the transcriptional coactivator p300 
(Hassa et al., 2001, 2003). Whether the enzymatic activity of 
PARP-1 is required for the enhanced transcriptional activity of 
NF-κB is a matter of dispute. Some reports show that enzymatic 
activity is not required for coactivation of NF-κB by p300 in 
TNF- or LPS-stimulated primary fi broblasts or macrophages 
(Hassa et al., 2003; Petrilli et al., 2004). However, other studies 
using PARP-1 inhibitors do indicate a role for PARP-1 enzy-
matic activity in the enhancement of NF-κB transcriptional ac-
tivity (Chiarugi and Moskowitz, 2003; Nakajima et al., 2004). 
The strong phenotype of the caspase-resistant PARP-1 knock-in 
mice, such as their resistance to endotoxic shock and to intesti-
nal and renal ischemia-reperfusion, further support an in vivo 
contribution of executioner caspases to infl ammatory responses 
through PARP-1 cleavage. Hence, caspase-mediated PARP-1 
cleavage under nonapoptotic conditions could contribute to the 
level of NF-κB transcriptional activity.
The possible role of executioner caspases in the activation 
of NF-κB may at least partially explain the multitude of non-
apoptotic functions that have recently been attributed to this 
caspase subfamily. For example, caspase-3 was reported to be 
active in the nuclei of dividing cells in the proliferative regions 
of the rat forebrain (Yan et al., 2001). Furthermore, caspase-
 dependent cleavage of p27KIP1 occurs in proliferating lymphoid 
cells (Frost et al., 2001), and B cells from caspase-3–defi cient 
mice can hyperproliferate (Woo et al., 2003). The latter fi nding 
indicates that caspase-3 may function as a negative regulator of 
B cell cycling. In this respect, caspase-3 was shown to be re-
quired for the cleavage of the Cdk inhibitor p21 in B cells (Woo 
et al., 2003). Similar studies in conditional knock-out mice may 
reveal additional roles for caspases in cell cycle regulation.
Conclusions and perspectives
In summary, two main mechanisms of caspase-mediated 
NF-κB activation can be distinguished. The prodomains of the 
 initiator caspases-1, -2, and -8 can engage in NF-κB signaling 
Table I. Comparison of phenotypes related to TcR-induced proliferation and NF-𝛋B activation in different human and mouse models
Protein Phenotype Reference
FADD Deﬁ cient
FADD is required for TcR-induced proliferation in murine T cells (Zhang et al., 1998; 
 Zhang et al., 2005)
Transgene
Dominant-negative FADD (FADD-DN)-expressing murine T cells display proliferative defects following 
 TcR activation
(Newton et al., 1998; 
 Arechiga et al., 2005)
FADD-DN does not block TcR-mediated NF-κB activation (Arechiga et al., 2005)
Caspase-8 Deﬁ cient
Caspase-8–deﬁ cient mouse T cells show defective TcR-induced proliferation, but NF-κB activation not affected (Salmena et al., 2003)
Caspase-8–deﬁ cient human T cells show hampered NF-κB activation upon TcR stimulation. Caspase-8 
 enzymatic activity required for TcR-induced NF-κB.
(Su et al., 2005)
cFLIP Deﬁ cient
cFLIP−/− mouse T cells are impaired in proliferation in response to TcR stimulation (Chau et al., 2005; 
 Zhang and He, 2005)
TcR-induced NF-κB activation in cFLIP−/− thymocytes appears intact (Zhang and He, 2005)
Transgene
cFLIP transgene in T cell compartment shows spontaneous loss of IkBα, which may reﬂ ect activation of NF-κB (Kataoka et al., 2000)
Suboptimal doses of TcR stimulation reveal increased proliferation in cFLIP transgenic T cells (Lens et al., 2002)
Increased NF-κB activation upon TcR triggering of cFLIP transgenic T cells (Dohryman et al., 2005)
Suppressed TcR-induced proliferation in cFLIP transgenic T cells (Tai et al., 2004)
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through the recruitment of NF-κB–signaling molecules such as 
TRAF-2/RIP-1 or TRAF-6/RIP-2. However, we are aware that 
most of these data are still based on overexpression studies and 
the physiological relevance of these pathways should be further 
addressed. On the other hand, limited levels of caspase activa-
tion and substrate cleavage allow both initiator and executioner 
caspases to operate in nonapoptotic functions such as NF-κB 
activation. The exact caspase-dependent signaling pathways to 
gene activation remain to be determined. Regardless of the sig-
naling mechanism involved, NF-κB activation can prevent the 
induction of apoptosis by up-regulating anti-apoptotic mecha-
nisms such as anti-apoptotic Bcl-2 family members (Wang 
et al., 1999), inhibitor of apoptosis proteins (IAPs) (Weber and 
Menko, 2005), and FLIPL (Micheau et al., 2002). This is in 
marked contrast to conditions of full-blown proteolytic activa-
tion of caspases observed during apoptosis. The concomitant 
proteolysis of apoptosis-associated substrates results in the re-
lease of pro-apoptotic mitochondrial factors in the cytosol, thus 
strongly enhancing the apoptotic outcome. Altogether, the in-
volvement of caspases in nonapoptotic functions suggests that 
therapeutic inhibition of caspase activity to prevent cell death 
may have broader implications than initially conceived.
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